AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 286: H2113-H2117, 2004. First published February 12, 2004; doi:10.1152/ajpheart.01054.2003
0363-6135/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/6/H2113    most recent
01054.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monahan, K. D.
Right arrow Articles by Seals, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monahan, K. D.
Right arrow Articles by Seals, D. R.

Ascorbic acid increases cardiovagal baroreflex sensitivity in healthy older men

Kevin D. Monahan,1 Iratxe Eskurza,1 and Douglas R. Seals1,2

1Department of Integrative Physiology, University of Colorado at Boulder, Boulder 80309; and 2Divisions of Cardiology and Geriatric Medicine, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262

Submitted 5 November 2003 ; accepted in final form 9 February 2004


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cardiovagal baroreflex sensitivity (BRS) declines with advancing age in healthy men. We tested the hypothesis that oxidative stress contributes mechanistically to this age-associated reduction. Eight young (23 ± 1 yrs, means ± SE) and seven older (63 ± 3) healthy men were studied. Cardiovagal BRS was assessed using the modified Oxford technique (bolus infusion of 50–100 µg sodium nitroprusside, followed 60 s later by a 100- to 150-µg bolus of phenylephrine hydrochloride) in triplicate at baseline and during acute intravenous ascorbic acid infusion. At baseline, cardiovagal BRS (slope of the linear portion of the R-R interval-systolic blood pressure relation during pharmacological changes in arterial blood pressure) was 56% lower (P < 0.01) in older (8.3 ± 1.6 ms/mmHg) compared with young (19.0 ± 3.1 ms/mmHg) men. Ascorbic acid infusion increased plasma concentrations similarly in young (62 ± 9 vs. 1,249 ± 72 µmol/l for baseline and during ascorbic acid; P < 0.05) and older men (62 ± 4 vs. 1,022 ± 55 µmol/l; P < 0.05) without affecting baseline blood pressure, heart rate, carotid artery compliance, or the magnitude of change in systolic blood pressure in response to bolus sodium nitroprusside and phenylephrine hydrochloride infusion. Ascorbic acid (vitamin C) infusion increased cardiovagal BRS in older ({Delta}58 ± 16%; P < 0.01), but not younger ({Delta} – 4 ± 4%) men. These data provide experimental support for the concept that oxidative stress contributes mechanistically to age-associated reductions in cardiovagal BRS in healthy men.

baroreceptors; blood pressure; antioxidants

THE SLOPE RELATING CONSECUTIVE cardiac periods (R-R intervals) and systolic blood pressures (SBP) during acute changes in arterial BP has become a widely accepted method of quantifying cardiovagal baroreflex sensitivity (BRS) in humans (2, 3, 33). Depressed cardiovagal responsiveness has been linked to impaired BP regulation with aging (32) and an increased incidence of sudden cardiac death in patients with coronary artery disease (19, 20). Thus the identification of mechanisms underlying depressed cardiovagal BRS has important clinical implications.

Many cardiovascular disease states are associated with baroreflex impairment (4, 10), with oxidative stress playing a possible mechanistic role (22, 27, 28). Aging, which is a primary risk factor for cardiovascular disease development (21), is associated with a reduction in cardiovagal BRS (9, 13, 25) and increased levels of oxidative stress (15, 17, 18, 40). However, it is unknown whether these events are mechanistically linked. Increased levels of oxidative stress with age could impair baroreflex function through a direct suppressive influence on baroreceptors (22). In addition, because nitric oxide appears to be an important modulator of baroreflex function in humans (7, 35), and its bioavailability is reduced with age (37), it is possible that oxidative stress could suppress baroreflex function indirectly by reducing nitric oxide bioavailability (29, 37).

We tested the hypothesis that oxidative stress contributes to the age-associated reduction in cardiovagal BRS. To address this hypothesis, cardiovagal BRS was determined at baseline and during acute intravenous infusion of the powerful antioxidant ascorbic acid (11) in young and older healthy men.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Subjects

Fifteen men were studied after obtaining University of Colorado-approved written informed consent. All subjects were sedentary and between the ages of 20–35 (young) or 55–79 (older) yr. All subjects were normotensive (BP <140/90 mmHg), nonobese (BMI <27 kg/m2), nonsmokers, not taking any medications, and free of cardiovascular disease as assessed by history and physical examination, blood chemistries, and maximal exercise BP and electrocardiograms (older subjects only). No subjects took vitamin or antioxidant supplements for at least 6 wk before testing.

Measurements

Subjects were studied at least 4 h postprandial (12 h for screening blood chemistries).

Cardiovagal BRS. During these measurements, subjects were studied supine 30 min after being instrumented with an intravenous cannula for infusion of sodium nitroprusside, phenylephrine hydrochloride, and ascorbic acid and for continuous cardiac period (5-lead ECG) and beat-to-beat BP (Finapres-Ohmeda) measurements. Physiological data were digitally recorded on a personal computer.

Cardiovagal BRS was assessed using the modified Oxford technique (8, 30). Briefly, sodium nitroprusside was infused intravenously (50–100 µg) as a bolus, followed 60 s later by a bolus of phenylephrine hydrochloride (75–150 µg). Data acquisition began ~10 s before sodium nitroprusside infusion and continued for 120 s after phenylephrine hydrochloride infusion. Drugs were administered at doses sufficient to elicit the desired effects on SBP (~15–25 mmHg reduction and subsequent increase in SBP from baseline levels).

Cardiovagal BRS was quantified by a blinded investigator as the slope of the R-R interval-SBP relation (binned over 2 mmHg pressure ranges) from the nadir to peak SBP response during the trial (8, 30). Data points clearly contained within either the threshold or saturation regions were manually removed (14). After this process, all BRS trials (<=3) with linear regression coefficients exceeding an r value of 0.70 were averaged together under each condition (e.g., baseline and ascorbic acid) and a single mean value was reported (30, 33). With the use of this approach, each individual's cardiovagal BRS value under each condition (e.g., baseline and ascorbic acid) included the average of two (n = 9) and, in some instances, three trials (n = 6).

Carotid artery compliance. Carotid artery compliance was measured under resting supine conditions as previously described by our laboratory (39). Briefly, pulsatile common carotid artery images, obtained using an ultrasound machine with a high-resolution probe, were recorded to a personal computer. Simultaneously, carotid arterial pressure waveforms were obtained noninvasively with applanation tonometry (model TCB-500, Millar Instruments) over the contralateral common carotid artery to obtain estimates of central BP. Carotid artery end-diastolic and end-systolic diameters were measured off-line. Carotid artery compliance was then calculated from these measures (41).

Vitamin C concentrations. Plasma vitamin C concentrations were measured at baseline, after the priming dose, and at the end of the protocol (11).

Resting BP and heart rate. Resting BP was determined using an automated device (Dinamap XL, Johnson & Johnson). Heart rate was determined from the ECG.

Body composition. Body composition was determined using dual energy X-ray absorptiometry (Lunar Radiation).

Maximal oxygen consumption. Maximal aerobic capacity was determined during incremental treadmill exercise to exhaustion using open circuit spirometry as previously described (36).

Protocol

Three cardiovagal BRS trials were performed at baseline and three trials were performed during ascorbic acid infusion. The latter consisted of a priming dose of 0.06 g/kg of fat-free mass administered over 20 min, followed by a maintenance dose of 0.03 g/kg fat-free mass. The total absolute dose of ascorbic acid infused was >4 g and <5 g in every subject. Three ascorbic acid cardiovagal BRS trials were performed during the maintenance dose. Pilot testing established that this infusion protocol increased plasma ascorbic acid concentrations to levels previously shown to scavenge free radicals (1,000 µmol/l) (16). Fifteen minutes elapsed between each trial. Carotid artery compliance was determined before and at least 30 min after the completion of the vasoactive drug infusions.

Statistical Analysis

Differences in baseline subject characteristics were determined by t-test and repeated-measures ANOVA was used to determine the effects of ascorbic acid. Specific contrasts were made using Newman-Keuls post hoc tests. Relations between variables were determined with correlation analyses. Statistical significance occurred at P < 0.05.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Subject Characteristics

Subject characteristics at baseline and after ascorbic acid are shown in Table 1. Ascorbic acid concentrations were similar in the two groups at baseline and increased to supraphysiological levels (~15-fold; >1,000 µmol/l throughout the measurement period) in both groups without affecting baseline BP, heart rate, or carotid artery compliance in either group.


View this table:
[in this window]
[in a new window]
  		Table 1. Subject characteristics

 
Cardiovagal BRS

At baseline, cardiovagal BRS was 56% lower in older (8.3 ± 1.6 ms/mmHg) compared with young (19.0 ± 3.1 ms/mmHg; P < 0.05) men. Ascorbic acid infusion increased cardiovagal BRS by 58 ± 16% in older men (to 13.1 ± 2.4 ms/mmHg; P < 0.01), but had no effect in young men (18.3 ± 2.7 ms/mmHg; {Delta} – 4 ± 4%) (Fig. 1 and Fig. 2, bottom). After ascorbic acid infusion, the age-associated difference in cardiovagal BRS was no longer statistically significant (P = 0.17). Ascorbic acid-induced increases in cardiovagal BRS were consistent and robust among the older men (Fig. 2, top). Indeed, the increase in cardiovagal BRS with ascorbic acid in every older subject exceeded the maximal increase noted in any young subject (Fig. 2, top). Similar results were obtained when BRS was expressed as the linear portion of the SBP-heart rate relation. Specifically, BRS expressed in this manner was lower in older (–0.46 ± 0.08 beats·min–1·mmHg–1) compared with young men (–0.94 ± 0.08 beats·min–1·mmHg–1; P < 0.001) and was increased in older (–0.66 ± 0.12 beats·min–1·mmHg–1; P < 0.05), but not young men (–0.86 ± 0.09 beats·min–1·mmHg–1) when measured during ascorbic acid infusion.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 1. Cardiovagal baroreflex sensitivity (BRS) before (baseline) and after intravenous ascorbic acid in young men (open bars) and older men (solid bars). ANOVA interaction term P < 0.001. *P < 0.05 vs. young at same time point; {dagger}P < 0.05 vs. baseline.

 


View larger version (9K):
[in this window]
[in a new window]
  		Fig. 2. Subject-by-subject (top) and group response (bottom) of the relative improvement (%change from baseline) in cardiovagal BRS with ascorbic acid infusion. *P < 0.05 vs. young; {dagger}P < 0.05 vs. baseline.

 
During both the baseline and ascorbic acid BRS trials, the maximal decrease in SBP observed after sodium nitroprusside infusion was similar in young ({Delta}17 ± 2 vs. {Delta}18 ± 3 mmHg for baseline and ascorbic acid trials) and older subjects ({Delta}19 ± 2 vs. {Delta}17 ± 2 mmHg). In addition, the maximal increase in SBP above baseline levels after phenylephrine hydrochloride infusion was similar in young ({Delta}21 ± 2 vs. {Delta}20 ± 2 mmHg for baseline and ascorbic acid trials) and older subjects ({Delta}22 ± 2 vs. {Delta}26 ± 2 mmHg).

Correlates of BRS

At baseline, cardiovagal BRS was significantly related to age (r = –0.63), carotid artery compliance (r = 0.55), and resting heart rate (r = –0.55) in all subjects (n = 15). No subject characteristic or baseline cardiovascular function correlated significantly with the improvements in cardiovagal BRS with ascorbic acid in the older men.


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The novel finding from the present study is that acute intravenous ascorbic acid administration increases cardiovagal BRS in older men without clinical disease. This suggests that oxidative stress contributes mechanistically to the age-associated reduction in cardiovagal BRS observed in healthy men.

There is mounting experimental evidence that oxidative stress modulates baroreflex function. In rabbits with experimentally induced atherosclerosis, depressed baseline baroreceptor function was improved after exposing the carotid sinus to exogenous free radical scavenging superoxide dismutase and catalase (22). These data suggest a direct suppressive action of reactive oxygen species on carotid baroreceptors. Moreover, acute intravenous infusion of ascorbic acid increases cardiovagal BRS in patients with congestive heart failure (27, 28). Importantly, administration of antioxidants in these previous investigations, as well as in the present study, had no effect on baroreflex function in healthy young controls (22, 27), suggesting that ascorbic acid administration in the absence of oxidative stress has no influence on cardiovagal BRS. Consistent with this suggestion, exogenous administration of xanthine and xanthine oxidase, which cause oxidative stress, also impairs baroreceptor function in young rabbits (22). Collectively, the results of the present study and these previous studies support the concept that oxidative stress impairs BRS in the settings of both aging and cardiovascular disease.

It is not possible to determine the site at which ascorbic acid exerted its positive influence on baroreflex function in older men in the present study. As described above, data derived from animals strongly suggest a direct suppressive influence of reactive oxygen species on baroreceptors (i.e., a peripheral site of action) (22). However, a central effect of ascorbic acid cannot be excluded in the present study. Ascorbic acid infused systemically can cross the blood-brain barrier (1). However, this transport necessitates that ascorbic acid first be oxidized to dehydroascorbic acid (1). This process likely explains why intravenously infused ascorbic acid cannot be detected in the cerebrospinal fluid for at least 30 min after systemic infusion in rodents (34). These temporal patterns have not been established in humans. Therefore, we cannot exclude the possibility that ascorbic acid exerted a central effect in the older men and contributed to the increased levels of cardiovagal BRS observed during ascorbic acid administration.

In addition to the possibility that ascorbic acid increases cardiovagal BRS in older men due to a direct influence of reducing reactive oxygen species, it is possible that the observed effects are not direct. For example, nitric oxide has been suggested to play an important role in autonomic and baroreflex control in humans (5–7, 35). Because sedentary aging in humans is associated with a reduction in nitric oxide bioavailability (37, 38), which is caused primarily by oxidative stress, it is possible that reduced bioavailability of nitric oxide may contribute to depressed levels of cardiovagal BRS in older men secondary to increased levels of oxidative stress. Thus infusion of ascorbic acid in older adults may increase the bioavailability of nitric oxide (37), which then could exert positive influences on regions critical to the regulation of autonomic outflow such as the nucleus tractus solitarii (23) or via a direct influence on the sinoatrial node (42). We made no measure of nitric oxide bioavailability in the present study. Therefore, we can only speculate that ascorbic acid may increase cardiovagal BRS secondary to increased bioavailability of nitric oxide.

A recent study (28) reported that intravenous ascorbic acid infusion did not improve cardiovagal BRS in healthy middle-aged adults. At least two points should be considered when interpreting these results in the context of the present findings. First, our subjects were older (mean age 63 vs. 55 yr). Because oxidative stress develops (15, 17, 18, 40) and cardiovagal BRS decreases with age (9, 13, 25), it is likely that studying individuals who were older enhanced our ability to detect an improvement in cardiovagal BRS with ascorbic acid. Second, our dose of ascorbic acid was considerably larger than in this recent investigation, and it is well established that the antioxidant properties of ascorbic acid are dose dependent (16, 31). Moreover, because plasma concentrations of ascorbic acid were not reported in this prior study, it cannot be determined whether circulating ascorbic acid achieved levels known to scavenge reactive oxygen species in healthy adults, as was carefully documented in the present study.

The mechanism underlying the increase in cardiovagal BRS with ascorbic acid in older men is unclear. At baseline, we demonstrated an association between the compliance of an artery in which baroreceptors are located (carotid) and cardiovagal BRS (r = 0.55), which is consistent with our previous findings (24, 26). However, the lack of relation between changes in cardiovagal BRS and carotid artery compliance from baseline in response to ascorbic acid infusion in older men suggests a compliance-independent effect of oxidative stress on cardiovagal BRS, consistent with previous data in experimental animals (22). Collectively, these observations indicate that oxidative stress influences some other aspect of the baroreflex, such as exerting a direct effect on baroreceptors, modifying central integration of afferent barosensory stimuli, and/or altering end-organ responsiveness to alterations in cardiac-vagal nerve traffic.

Our findings may have important physiological and clinical implications. A growing body of evidence in humans indicates an association between impaired cardiovagal BRS and the incidence of sudden cardiac death (19, 20). Aging is associated with both a reduction in cardiovagal BRS (9, 13, 25) and an increased prevalence of lethal ventricular tachyarrhythmias (12). Thus it is possible that the age-related decline in cardiovagal BRS may predispose older adults to sudden cardiac death.

In the present study, we did not determine responses to a placebo infusion. However, we believe that our young subjects represent a valid and appropriate control group. Specifically, because oxidative stress is not present in healthy young adults, there is little experimental basis to hypothesize that ascorbic acid would exert a significant effect on baroreflex function. This suggestion is supported by the following: 1) cardiovagal BRS did not increase in our young controls in response to raising plasma ascorbic acid concentrations to levels associated with free radical scavenging, 2) no young subject demonstrated an increase in cardiovagal BRS that exceeded the minimal increase observed among the older subjects, and 3) intravenous ascorbic acid was shown previously not to alter cardiovagal BRS in young healthy adults (27), suggesting that baseline oxidative stress is a prerequisite for antioxidant-mediated improvements in cardiovagal BRS. Thus the collective body of published experimental data indicates that ascorbic acid should exert no effect in young healthy adults and supports their use as an appropriate control group. Finally, the fact that the cardiovagal BRS analyses were performed by an investigator who was blinded to the ages of the subjects ensures the validity of the group differences observed in the responses to ascorbic acid.

It is important to reemphasize that the stated aim of the present study was to test the hypothesis that oxidative stress contributes mechanistically to age-associated reductions in cardiovagal BRS, not to determine the efficacy of oral vitamin C supplementation as a potential intervention. However, recently a 4-wk intervention of daily oral vitamin C (4 g) showed no increase in cardiovagal BRS in heart failure patients (27). This lack of effect likely is explained by the fact that oral vitamin C supplementation fails to raise or maintain plasma ascorbic acid concentrations at levels required to scavenge reactive oxygen species (i.e., ~100 µmol/l compared with >=1,000 µmol/l during acute intravenous infusion in the present study).

We have no biomarkers of oxidative stress in the present study. If we had, these would be limited to systemic plasma markers, which may not accurately reflect oxidative stress at sites critical to the baroreflex function. However, we do establish a consistent and robust increase in cardiovagal BRS that was demonstrated during ascorbic acid infusion in older, but not young men. We are unaware of any antioxidant-independent effect of ascorbic acid that could provide an alternative explanation to our conclusions. Moreover, it is unlikely that ascorbic acid elicited an oxidative stress-independent change that would be selective to older adults. Therefore, we believe that our results can only be explained by an ascorbic acid-induced suppression of reactive oxygen species that was greater in older adults due to the presence of oxidative stress.

In conclusion, the present findings provide the first direct experimental support for the concept that oxidative stress contributes mechanistically to the age-associated reduction in cardiovagal BRS in healthy men. As such, interventions with the potential to tonically suppress oxidative stress (e.g., habitual exercise, weight loss, and perhaps oral antioxidant therapy) may have efficacy for augmenting BRS in older adults.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Institutes of Health Grants HL-67624, AG-13038, AG-06537, AG-19365, and RR-00051.


   ACKNOWLEDGMENTS
 
We thank Joshua Evans, Jed Robinson, and staff of the General Clinical Research Center on the University of Colorado-Boulder campus for technical assistance.


   FOOTNOTES
 

Address for reprint requests and other correspondence: K. D. Monahan, Penn State College of Medicine, Division of Cardiology H047, The Milton S. Hershey Medical Center, 500 Univ. Dr., Hershey, PA 17033-2390 (E-mail: kmonahan{at}psu.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, and Golde DW. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest 100: 2842–2848, 1997.[Web of Science][Medline]
  2. Bristow JD, Gribbin B, Honour AJ, Pickering TG, and Sleight P. Diminished baroreflex sensitivity in high blood pressure and ageing man. J Physiol 202: 45P-46P, 1969.[Medline]
  3. Bristow JD, Honour AJ, Pickering GW, Sleight P, and Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 39: 48–54, 1969.[Abstract/Free Full Text]
  4. Chapleau MW, Li Z, Meyrelles SS, Ma X, and Abboud FM. Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Ann NY Acad Sci 940: 1–19, 2001.[CrossRef][Web of Science][Medline]
  5. Chowdhary S, Andre Ng G, Nuttall SL, Coote JH, Ross HF, and Townend JN. Nitric oxide and cardiac parasympathetic control in human heart failure. Clin Sci (Lond) 102: 397–402, 2002.[Medline]
  6. Chowdhary S and Townend JN. Role of nitric oxide in the regulation of cardiovascular autonomic control. Clin Sci (Lond) 97: 5–17, 1999.[Medline]
  7. Chowdhary S, Vaile JC, Fletcher J, Ross HF, Coote JH, and Townend JN. Nitric oxide and cardiac autonomic control in humans. Hypertension 36: 264–269, 2000.[Abstract/Free Full Text]
  8. Ebert TJ and Cowley AW Jr. Baroreflex modulation of sympathetic outflow during physiological increases of vasopressin in humans. Am J Physiol Heart Circ Physiol 262: H1372–H1378, 1992.[Abstract/Free Full Text]
  9. Ebert TJ, Morgan BJ, Barney JA, Denahan T, and Smith JJ. Effects of aging on baroreflex regulation of sympathetic activity in humans. Am J Physiol Heart Circ Physiol 263: H798–H803, 1992.[Abstract/Free Full Text]
  10. Eckberg DL and Sleight P. Human Baroreflexes in Health and Disease. Oxford, UK: Clarendon, 1992.
  11. Frei B, England L, and Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377–6381, 1989.[Abstract/Free Full Text]
  12. Gilman JK, Jalal S, and Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation 90: 1083–1092, 1994.[Abstract/Free Full Text]
  13. Gribbin B, Pickering TG, Sleight P, and Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 29: 424–431, 1971.[Abstract/Free Full Text]
  14. Halliwill JR and Minson CT. Effect of hypoxia on arterial baroreflex control of heart rate and muscle sympathetic nerve activity in humans. J Appl Physiol 93: 857–864, 2002.[Abstract/Free Full Text]
  15. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, and Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 37: 529–534, 2001.[Abstract/Free Full Text]
  16. Jackson TS, Xu A, Vita JA, and Keaney JF Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 83: 916–922, 1998.[Abstract/Free Full Text]
  17. Kasapoglu M and Ozben T. Alterations of antioxidant enzymes and oxidative stress markers in aging. Exp Gerontol 36: 209–220, 2001.[CrossRef][Web of Science][Medline]
  18. Knight JA. The biochemistry of aging. Adv Clin Chem 35: 1–62, 2000.[Web of Science][Medline]
  19. La Rovere MT, Bigger JT, Marcus FI, Mortara A, and Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 351: 478–484, 1998.[CrossRef][Web of Science][Medline]
  20. La Rovere TM, Specchia G, Mortara A, and Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 78: 816–824, 1988.[Abstract/Free Full Text]
  21. Lakatta EG and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a "set up" for vascular disease. Circulation 107: 139–146, 2003.[Free Full Text]
  22. Li Z, Mao HZ, Abboud FM, and Chapleau MW. Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res 79: 802–811, 1996.[Abstract/Free Full Text]
  23. Ma S, Abboud FM, and Felder RB. Effects of l-arginine-derived nitric oxide synthesis on neuronal activity in nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 268: R487–R491, 1995.[Abstract/Free Full Text]
  24. Monahan KD, Dinenno FA, Seals DR, Clevenger CM, DeSouza CA, and Tanaka H. Age-associated changes in cardiovagal baroreflex sensitivity are related to central arterial compliance. Am J Physiol Heart Circ Physiol 281: H284–H289, 2001.[Abstract/Free Full Text]
  25. Monahan KD, Dinenno FA, Tanaka H, Clevenger CM, DeSouza CA, and Seals DR. Regular aerobic exercise modulates age-associated declines in cardiovagal baroreflex sensitivity in healthy men. J Physiol 529, Pt 1: 263–271, 2000.[Abstract/Free Full Text]
  26. Monahan KD, Tanaka H, Dinenno FA, and Seals DR. Central arterial compliance is associated with age- and habitual exercise-related differences in cardiovagal baroreflex sensitivity. Circulation 104: 1627–1632, 2001.[Abstract/Free Full Text]
  27. Nightingale AK, Blackman DJ, Field R, Glover NJ, Pegge N, Mumford C, Schmitt M, Ellis GR, Morris-Thurgood JA, and Frenneaux MP. Role of nitric oxide and oxidative stress in baroreceptor dysfunction in patients with chronic heart failure. Clin Sci (Lond) 104: 529–535, 2003.[Medline]
  28. Piccirillo G, Nocco M, Moise A, Lionetti M, Naso C, di Carlo S, and Marigliano V. Influence of vitamin C on baroreflex sensitivity in chronic heart failure. Hypertension 41: 1240–1245, 2003.[Abstract/Free Full Text]
  29. Rubanyi GM and Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 250: H822–H827, 1986.[Abstract/Free Full Text]
  30. Rudas L, Crossman AA, Morillo CA, Halliwill JR, Tahvanainen KU, Kuusela TA, and Eckberg DL. Human sympathetic and vagal baroreflex responses to sequential nitroprusside and phenylephrine. Am J Physiol Heart Circ Physiol 276: H1691–H1698, 1999.[Abstract/Free Full Text]
  31. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, and Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35: 936–941, 2000.[Abstract/Free Full Text]
  32. Shi X, Walter DW, Formes KJ, Wang HW, Hayes PM, OYurvati AH, Weiss MS, and Reese IP. Orthostatic hypotension in aging humans. Am J Physiol Heart Circ Physiol 279: H1548–H1554, 2000.[Abstract/Free Full Text]
  33. Smyth HS, Sleight P, and Pickering GW. Reflex regulation of arterial pressure during sleep in man: a quantitative method of assessing baroreflex sensitivity. Circ Res 24: 109–121, 1969.[Abstract/Free Full Text]
  34. Spector R. Vitamin homeostasis in the central nervous system. N Engl J Med 296: 1393–1398, 1977.[Web of Science][Medline]
  35. Spieker LE, Corti R, Binggeli C, Luscher TF, and Noll G. Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans. J Am Coll Cardiol 36: 213–218, 2000.[Abstract/Free Full Text]
  36. Stevenson ET, Davy KP, and Seals DR. Maximal aerobic capacity and total blood volume in highly trained middle-aged and older female endurance athletes. J Appl Physiol 77: 1691–1696, 1994.[Abstract/Free Full Text]
  37. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, and Salvetti A. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 38: 274–279, 2001.[Abstract/Free Full Text]
  38. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, and Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 91: 1981–1987, 1995.[Abstract/Free Full Text]
  39. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, and Seals DR. Aging, habitual exercise, and dynamic arterial compliance. Circulation 102: 1270–1275, 2000.[Abstract/Free Full Text]
  40. Van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios-Callender M, Erusalimsky JD, Quaschning T, Malinski T, Gygi D, Ullrich V, and Luscher TF. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192: 1731–1744, 2000.[Abstract/Free Full Text]
  41. Van Merode T, Hick PJ, Hoeks AP, Rahn KH, and Reneman RS. Carotid artery wall properties in normotensive and borderline hypertensive subjects of various ages. Ultrasound Med Biol 14: 563–569, 1988.[CrossRef][Web of Science][Medline]
  42. Zanzinger J, Czachurski J, and Seller H. Inhibition of basal and reflex-mediated sympathetic activity in the RVLM by nitric oxide. Am J Physiol Regul Integr Comp Physiol 268: R958–R962, 1995.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
K. L. Jablonski, D. R. Seals, I. Eskurza, K. D. Monahan, and A. J. Donato
High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men
J Appl Physiol, November 1, 2007; 103(5): 1715 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. Cui, S. Durand, and C. G. Crandall
Baroreflex control of muscle sympathetic nerve activity during skin surface cooling
J Appl Physiol, October 1, 2007; 103(4): 1284 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. D. Monahan
Effect of aging on baroreflex function in humans
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R3 - R12.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
K. L. Moreau, A. R. DePaulis, K. M. Gavin, and D. R. Seals
Oxidative stress contributes to chronic leg vasoconstriction in estrogen-deficient postmenopausal women
J Appl Physiol, March 1, 2007; 102(3): 890 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. D. Monahan, U. A. Leuenberger, and C. A. Ray
Aldosterone impairs baroreflex sensitivity in healthy adults
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H190 - H197.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
K. D. Monahan, U. A. Leuenberger, and C. A. Ray
Effect of repetitive hypoxic apnoeas on baroreflex function in humans
J. Physiol., July 15, 2006; 574(2): 605 - 613.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
X. Yang, T. A. Doser, C. X. Fang, J. M. Nunn, R. Janardhanan, M. Zhu, N. Sreejayan, M. T. Quinn, and J. Ren
Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress
FASEB J, May 1, 2006; 20(7): 1024 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. E. Alvarez, B. M. Davy, T. P. Ballard, S. D. Beske, and K. P. Davy
Weight loss increases cardiovagal baroreflex function in obese young and older men
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E665 - E669.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
K. L. Moreau, K. M. Gavin, A. E. Plum, and D. R. Seals
Ascorbic Acid Selectively Improves Large Elastic Artery Compliance in Postmenopausal Women
Hypertension, June 1, 2005; 45(6): 1107 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. Bell, J. M. Carson, N. W. Motte, and D. R. Seals
Ascorbic acid does not affect the age-associated reduction in maximal cardiac output and oxygen consumption in healthy adults
J Appl Physiol, March 1, 2005; 98(3): 845 - 849.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/6/H2113    most recent
01054.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monahan, K. D.
Right arrow Articles by Seals, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monahan, K. D.
Right arrow Articles by Seals, D. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.